Abbott stent beats Boston Sci in outcomes study; AMA to probe journal allegations;

> Abbott Laboratories' Xience stent beat out Boston Scientific's Taxus products in a three-year study, with Xience patients suffering fewer heart attacks, deaths or repeat procedures. Report

> The American Medical Association is launching a probe of two JAMA editors' conduct after allegations surfaced that a study author failed to disclose a potential conflict of interest. Report

> AstraZeneca said an FDA advisory committee would review expanded use of Seroquel--treating schizophrenia in adolescents and bipolar mania in children and adolescents--at a meeting in June. Report

> Biogen Idec tapped Robert Hamm as its new chief operating officer, replacing Hans Peter Hasler; Hamm had been executive vice president for pharmaceutical operations and technology. Report

> Ranbaxy Laboratories posted a lost of $204 million for its fiscal 2008 on a 9.85 percent increase in revenues for the year. Report

> Amylin Pharmaceuticals announced two independent nominees to its board: Paul N. Clark, former chief of Icos Corp.; and Paulo F. Costa, former CEO of Novartis U.S. Release

> Akorn tapped CFO Jeffrey A. Whitnell to serve as interim CEO while the company searches for a permanent chief. Report

> Taiwan's Cabinet wants to make biotechnology the country's third major industry in the next 10 years. To that end, it has proposed a $1.76 billion dollar VC fund. Report

> Germany's Evotec is cutting 50 jobs as part of a restructuring plan designed to "significantly reduce its operating costs." Cuts will be accompanied by a 10 percent reduction in selling, general and administrative expenses, and a 30 percent slash in R&D spending. Report

> The drop in in early-stage research is having a substantial impact on CROs. Report

> Osiris Therapeutics has ended enrollment in a late-stage trial of Prochymal for Crohn's disease, saying that it believes that a design flaw spurred an unexpected placebo response. And that placebo response, the company said in a statement this morning, would have prevented its therapy from achieving its primary endpoint. Report

> Several developers will put the FDA's tougher safety standard for diabetes drugs to the test in coming months as they push for a slate of new approvals. Report

> Shares of Belgium's Galapagos surged on today's news that researchers had pushed its experimental therapy for rheumatoid arthritis into a Phase I human trial. Report

> Shares of Dyax took a beating as the FDA refused to approve DX-88, the company's treatment for hereditary angioedema (HAE) attacks. Report

And Finally... Greg Critser, author of Generation Rx, says drug companies have transformed themselves from science enterprises into consumer-goods companies. Report

Suggested Articles

Pfizer’s Ibrance has met with success in breast cancer since breaking onto the scene in 2015. But its first foray into early breast cancer was a bust.

After years of having first-line liver cancer market to itself, Bayer’s Nexavar is getting major competition from Roche's Tecentriq.

Most of the recent enthusiasm around AbbVie’s new drugs has centered on Skyrizi and Rinvoq, but elagolix wants a piece of the spotlight, too.